Researchers at Memorial Sloan Kettering Cancer Center have made a dual breakthrough in understanding ferroptosis — literally "death by iron" — a form of programmed cell death that could revolutionize cancer treatment. Dr. Xuejun Jiang's team discovered that metastatic cancer cells are far more vulnerable to ferroptosis than normal cells because they lose contact with neighboring cells, activating a protein called YAP that makes them susceptible to iron-driven death.
In a parallel study published in Developmental Cell, Dr. Michael Overholtzer's lab found the key to how ferroptosis spreads between cells: lysosomes — the cell's recycling centers — must rupture, releasing enzymes and iron ions that trigger a domino effect of cell death in neighboring cells. Depleting antioxidants like glutathione shifts cells toward necrosis, enabling collective tumor destruction.
The findings suggest that future drugs could exploit these ferroptotic chain reactions to wipe out drug-resistant tumors that survive conventional therapies. Mesothelioma cells with Merlin (NF2) mutations are particularly vulnerable, potentially serving as biomarkers. No FDA-approved ferroptosis-inducing drugs exist yet, but pharmaceutical companies are actively developing them.
